OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OKYO Pharma Limited has announced that its Executive Chairman, Gabriele Cerrone, through Panetta Partners Limited, has increased his stake in the company by purchasing 50,000 ordinary shares at $1.03 each, now holding a 29.12% interest. This biopharmaceutical firm focuses on developing treatments for inflammatory dry eye disease (DED) and neuropathic corneal pain (NCP), with OK-101—a novel drug candidate—showing promise in a Phase 2 trial for DED. OKYO Pharma is listed on NASDAQ and is advancing towards a Phase 2 trial for OK-101 to address NCP, aiming to serve a market lacking FDA-approved therapies.
For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.